Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast Cancer

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.

Two phase I trials are underway, looking at ONT-380 in combination with T-DM1 and in combination with capecitabine and trastuzumab.

A phase I trial with ONT-380 has been evaluated in this population of patients as well as a few patients with HER2-positive gastric cancer, Kirkman says. This analysis showed that ONT-380 is well tolerated and EGFR-related side effects were not observed. In a highly-pretreated population of patients with HER2-positive breast cancer, ONT-380 elicited a clinical benefit rate of 27%.